PMID- 35868653
OWN - NLM
STAT- MEDLINE
DCOM- 20220726
LR  - 20220813
IS  - 2054-4774 (Print)
IS  - 2054-4774 (Electronic)
IS  - 2054-4774 (Linking)
VI  - 9
IP  - 1
DP  - 2022 Jul
TI  - Patient journey in erosive oesophagitis: real-world perspectives from US 
      physicians and patients.
LID - 10.1136/bmjgast-2022-000941 [doi]
LID - e000941
AB  - OBJECTIVE: Management of erosive oesophagitis (EE) remains suboptimal, with many 
      patients experiencing incomplete healing, ongoing symptoms, and relapse despite 
      proton pump inhibitor (PPI) treatment. The Study of Acid-Related Disorders 
      investigated patient burden of individuals with EE in a real-world setting. 
      DESIGN: US gastroenterologists (GIs) or family physicians (FPs)/general 
      practitioners (GPs) treating patients with EE completed a physician survey and 
      enrolled up to four patients with EE for a patient survey, with prespecified data 
      extracted from medical records. RESULTS: 102 GIs and 149 FPs/GPs completed the 
      survey; data were available for 73 patients (mean age at diagnosis, 45.4 years). 
      Omeprazole was healthcare professional (HCP)-preferred first-line treatment 
      (60.8% GIs; 56.4% FPs/GPs), and pantoprazole preferred second line (29.4% and 
      32.9%, respectively). Price and insurance coverage (both 55.5% HCPs) and 
      familiarity (47.9%) key drivers for omeprazole; insurance coverage (52.0%), price 
      (50.0%), familiarity (48.0%), initial symptom relief (46.0%), and safety (44.0%) 
      key drivers for pantoprazole. Only 49.3% patients took medication as instructed 
      all the time; 56.8% independently increased medication frequency some of the 
      time. Despite treatment, 57.5% patients experienced heartburn and 30.1% 
      regurgitation; heartburn was the most bothersome symptom. 58.9% patients believed 
      that their symptoms could be better controlled; only 28.3% HCPs were very 
      satisfied with current treatment options. 83.6% patients wanted long-lasting 
      treatment options. Fast symptom relief for patients was a top priority for 66.1% 
      HCPs, while 56.6% would welcome alternatives to PPIs. CONCLUSION: This real-world 
      multicentre study highlights the need for new, rapidly acting treatments in EE 
      that reduce symptom burden, offer durable healing and provide symptom control.
CI  - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Vaezi, Michael F
AU  - Vaezi MF
AD  - Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical 
      Center, Nashville, Tennessee, USA michael.vaezi@vumc.org.
FAU - Brunton, Stephen
AU  - Brunton S
AD  - Primary Care Education Consortium, Winnsboro, Texas, USA.
FAU - Mark Fendrick, A
AU  - Mark Fendrick A
AD  - Department of Internal Medicine, University of Michigan Department of Internal 
      Medicine, Ann Arbor, Michigan, USA.
FAU - Howden, Colin W
AU  - Howden CW
AD  - University of Tennessee, Tennessee, Nashville, USA.
FAU - Atkinson, Christian
AU  - Atkinson C
AUID- ORCID: 0000-0002-9417-695X
AD  - Adelphi Real World, Bollington, Cheshire, UK.
FAU - Pelletier, Corey
AU  - Pelletier C
AD  - Phathom Pharmaceuticals, New Jersey, New Jersey, USA.
FAU - Jacob, Rinu
AU  - Jacob R
AD  - Phathom Pharmaceuticals, New Jersey, New Jersey, USA.
FAU - Spechler, Stuart J
AU  - Spechler SJ
AD  - Division of Gastroenterology, Baylor University Medical Center at Dallas, Dallas, 
      Texas, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - BMJ Open Gastroenterol
JT  - BMJ open gastroenterology
JID - 101660690
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - D8TST4O562 (Pantoprazole)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
MH  - *Anti-Ulcer Agents/adverse effects
MH  - Benzimidazoles/adverse effects
MH  - *Esophagitis/chemically induced/drug therapy/epidemiology
MH  - *Gastroesophageal Reflux/drug therapy/epidemiology
MH  - Heartburn/chemically induced/drug therapy
MH  - Humans
MH  - Omeprazole/therapeutic use
MH  - Pantoprazole/therapeutic use
MH  - *Peptic Ulcer/chemically induced/drug therapy
MH  - *Physicians
MH  - Proton Pump Inhibitors/therapeutic use
PMC - PMC9316025
OTO - NOTNLM
OT  - EROSIVE OESOPHAGITIS
OT  - GASTROESOPHAGEAL REFLUX DISEASE
OT  - QUALITY OF LIFE
COIS- Competing interests: CP and RJ are employees of Phathom Pharmaceuticals. All 
      other authors are consultants to Phathom Pharmaceuticals.
EDAT- 2022/07/23 06:00
MHDA- 2022/07/27 06:00
PMCR- 2022/07/22
CRDT- 2022/07/22 20:52
PHST- 2022/04/25 00:00 [received]
PHST- 2022/07/07 00:00 [accepted]
PHST- 2022/07/22 20:52 [entrez]
PHST- 2022/07/23 06:00 [pubmed]
PHST- 2022/07/27 06:00 [medline]
PHST- 2022/07/22 00:00 [pmc-release]
AID - bmjgast-2022-000941 [pii]
AID - 10.1136/bmjgast-2022-000941 [doi]
PST - ppublish
SO  - BMJ Open Gastroenterol. 2022 Jul;9(1):e000941. doi: 10.1136/bmjgast-2022-000941.